A Phase 2 interventional study of Nemolizumab and Nemolizumab in Moderate-to-Severe Atopic Dermatitis, sponsored by Galderma R&D. Completed at 23 sites in 5 countries. Open to participants aged 2 Years to 12 Years. Per ClinicalTrials.gov, last updated 2026-06-25.
Sponsored by Galderma R&D (part of Galderma Group AG) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 14 studies testing nemolizumab in Dermatitis, Atopic — 3 open to participants now, 3 under way, 1 of them phase 3. nemolizumab · Dermatitis, Atopic.
Among the 14 studies testing nemolizumab in Dermatitis, Atopic, this one is the 9th largest by enrollment, is one of 2 that started in 2021, is one of 7 in phase 2, and was the 9th registered.
1,594 studies on the registry are indexed under Dermatitis, Atopic; 287 are open to participants now.
Browse Dermatitis, Atopic studies →3 of the 14 studies testing nemolizumab in Dermatitis, Atopic are open now, in 2 countries. Recruiting first, the newest first:
Galderma R&D · Sites in China
Ages 12+
Galderma R&D · Sites in United States
Ages 6 mo–23 mo
University of California, San Francisco · Sites in United States
Ages 18+
By country, each count listing its studies:
nemolizumab: first FDA approval 2024 (NEMLUVIO), first EMA approval 2025. What it is approved for, and how studies give it, is on its page →
Of the 194 Dermatitis, Atopic studies recruiting now, 83 (43%) set no upper age limit and 95 (49%) stop at 75 or younger; 94 take children under 18; 51 take healthy volunteers.
This study: 2 Years to 12 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
14 studies; the count open now beside each. This study's row is marked.
First in 2013; this study’s year is marked. 2 started in 2021.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 109 is above the median of 82 across 1,248 interventional studies indexed under Dermatitis, Atopic.
Median enrollment 209 across the 14 interventional studies. Of the 10 that completed or were terminated, 9 (90%) have results posted.
This tab as a report to print or save as PDF → With an account.
13 of 14 have an industry lead sponsor. The 3 most frequent:
This study is registered under Galderma R&D, one of the names counted as Galderma Group AG. Under that name alone:
Galderma R&D is the lead sponsor of 284 studies on the registry; 11 are open to participants now.
Of its 60 completed or terminated interventional studies of FDA-regulated products, 55 (92%) have results posted.
17 studies in Dermatitis, Atopic by Galderma Group AG: 3 open now, 3 under way, 1 of them phase 3. Of 13 finished, 11 (85%) have results posted.
Among the 17 studies in Dermatitis, Atopic by Galderma Group AG, this one is the 9th largest by enrollment of the 16 interventional ones that give a count, is one of 2 that started in 2021, is one of 8 in phase 2, and was the 12th registered.
Galderma Group AG’s Dermatitis, Atopic studies by the year they started, since 2009.
1 of the studies testing nemolizumab in Dermatitis, Atopic that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07762833Phase 3Galderma R&DRandomized, Double-blind, Placebo-controlled Study of Nemolizumab in Chinese Subjects With Moderate-to-severe Atopic Dermatitis | 2027-10-28 |
Add it to your calendar (.ics) → With an account.
Among the 14 studies testing nemolizumab in Dermatitis, Atopic, from their registry updates:
Among Galderma Group AG’s 17 in Dermatitis, Atopic:
This tab as a report to print or save as PDF → With an account.
The purpose of this study was to assess the pharmacokinetics (PK), safety, and efficacy of nemolizumab in pediatric participants with moderate-to-severe atopic dermatitis (AD).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants aged 7-11 years will receive nemolizumab for 52 weeks.
Drug: Nemolizumab
Participants aged 7-11 years will receive nemolizumab for 52 weeks.
Drug: Nemolizumab
Participants aged 2-6 years will receive nemolizumab for 52 weeks.
Drug: Nemolizumab
Participants will receive subcutaneous (SC) injection of 10, 20 or 30 milligrams (mg) nemolizumab, every 4 weeks (Q4W) for 52 weeks with a loading dose of 20, 40 or 60 mg at Day 1 based on the body weight.
Also known as: CD14152
Participants will receive SC injection of 5, 10 or 15 mg nemolizumab, Q4W for 52 weeks with a loading dose of 10, 20 or 30 mg at Day 1 based on the body weight.
Also known as: CD14152
Nemolizumab Serum Concentrations
Serum concentrations of Nemolizumab were analyzed using validated enzyme linked immunosorbent assay (ELISA).
Time frame: At Weeks 4, 8, 12, 16, 32 and 52
Apparent Total Body Clearance (Cl/F) of Nemolizumab
CL/F is apparent clearance of the drug from the serum, calculated as the drug dose divided area under the curve from time 0 extrapolated to infinite time \[AUC (0-inf)\]. Individual nemolizumab.
Time frame: Pre-dose at Weeks 4, 8, 12, 16, 32 and 52
Apparent Volume of Distribution (Vd/F) of Nemolizumab
Vd/F was calculated as dose divided by lambda\_z \*AUC(0-inf).
Time frame: Pre-dose at Weeks 4, 8, 12, 16, 32 and 52
Absorption Rate Constant (Ka) of Nemolizumab
Time frame: Pre-dose at Weeks 4, 8, 12, 16, 32 and 52
Serum Concentration Observed Immediately Before Next Dosing (Ctrough) of Nemolizumab
Time frame: Pre-dose at Weeks 4, 8, 12, and 16
Area Under the Serum Concentration-Time Curve From Time Zero to Infinity (AUCinf) of Nemolizumab
Time frame: Pre-dose at Weeks 4, 8, 12, 16, 32 and 52
Apparent Terminal Half-life (t1/2) of Nemolizumab
Time frame: Pre-dose at Weeks 4, 8, 12, 16, 32 and 52
Number of Participants With Treatment Emergent Adverse Events (TEAEs), Adverse Events of Special Interest (AESIs), Adverse Events Leading to Discontinuation and Serious Adverse Events (SAEs)
AE defined as any untoward medical occurrence in clinical study participant administered a medicinal product which does not necessarily have causal relationship with this treatment. TEAEs defined as AEs occurring after first administration of study drug during the study. SAE was any untoward medical occurrence, in view of either Investigator or Sponsor, that resulted in death, was life-threatening, resulted in inpatient hospitalisation or prolongation of existing hospitalisation, resulted in persistent or significant disability/incapacity, was congenital anomaly/birth defect or was important medical event. AESI was noteworthy TEAE for study drug that was to be monitored closely and reported promptly. Relatedness to study drug was based on Investigator's discretion. AEs Leading to study treatment withdrawal and AEs Leading to study withdrawal will also be reported.
Time frame: Baseline through Week 52
Percent Change From Baseline in Eczema Area and Severity Index (EASI) Score at Each Visit up to Week 52
EASI assesses severity and extent of AD signs through a composite score of erythema, induration/population, excoriation, and lichenification. The severity was assessed on a scale of 0 (absent) to 3 (severe) for each of the 4 body areas: head/neck, trunk, upper limbs, and lower limbs, with half points allowed. The EASI score ranged from 0 to 72 with higher scores representing greater severity of atopic dermatitis.
Time frame: Baseline, Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48 and 52
Absolute Change From Baseline in EASI Score
EASI assesses severity and extent of AD signs through a composite score of erythema, induration/population, excoriation, and lichenification. The severity was assessed on a scale of 0 (absent) to 3 (severe) for each of the 4 body areas: head/neck, trunk, upper limbs, and lower limbs, with half points allowed. The EASI score ranged from 0 to 72 with higher scores representing greater severity of atopic dermatitis.
Time frame: Baseline, Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48 and 52
Number of Participants Achieving 50 Percent (%), 75% or 90% Response From Baseline in EASI (EASI-50, EASI-75 and EASI-90)
EASI assesses severity and extent of AD signs through a composite score of erythema, induration/population, excoriation, and lichenification. The severity was assessed on a scale of 0 (absent) to 3 (severe) for each of the 4 body areas: head/neck, trunk, upper limbs, and lower limbs, with half points allowed. The EASI score ranged from 0 to 72 with higher scores representing greater severity of atopic dermatitis. EASI-50, EASI-75 and EASI-90 responders will be the participants who achieved greater than or equal to (\>=) 50%, \>=75% and \>=90% overall improvement in EASI score respectively from baseline to Week 52.
Time frame: Baseline, Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48 and 52
Number of Participants With Investigator's Global Assessment (IGA) Success Rate
IGA is a 5-point scale used by the investigator or trained designee to evaluate the global severity of AD. The Investigator reviewed the participant's skin and give a score of 0 (Clear), 1 (Almost clear), 2 (Mild), 3 (Moderate), or 4 (Severe). Here, higher score indicates severe outcome. Success was defined as an IGA of 0 \[Clear\] or 1 \[Almost clear\] and a \>=2-points improvement from baseline. Number of participants with IGA success rate was reported for this outcome measure.
Time frame: Baseline, Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48 and 52
Change From Baseline in Body Surface Area (BSA) Involvement by Atopic Dermatitis (AD)
BSA affected by AD was assessed for each section of the body (the possible highest score for each region was: head and neck \[9%\], anterior trunk \[18%\], back \[18%\], upper limbs \[18%\], lower limbs \[36%\], and genitals \[1%\]) and reported as a percentage of all major body sections combined. The reported percentage of BSA was combined percentage of all major body sections.
Time frame: Baseline, Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48 and 52
Absolute Change From Baseline in Weekly Average of Peak Pruritus Numeric Rating Scale (PP NRS) Score
Pruritus NRS is a scale that will be used by the participants to report the intensity of their pruritus (itch) during the last 24 hours. For maximum itch intensity: the scores were provided on a scale of 0 to 10, with 0 being 'no itch' and 10 being 'worst itch imaginable'. Higher scores indicated worse outcome.
Time frame: Baseline, Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48 and 52
Percent Change From Baseline in Weekly Average of PP NRS Score
Pruritus NRS is a scale that was used by the participants to report the intensity of their pruritus (itch) during the last 24 hours. For maximum itch intensity: the scores were provided on a scale of 0 to 10, with 0 being 'no itch' and 10 being 'worst itch imaginable'. Higher scores indicated worse outcome.
Time frame: Baseline, Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48 and 52
Percentage of Participants With an Improvement of >= 4 From Baseline in Weekly Average of PP NRS
Pruritus NRS is a scale that was used by the participants to report the intensity of their pruritus (itch) during the last 24 hours. For maximum itch intensity: the scores were provided on a scale of 0 to 10, with 0 being 'no itch' and 10 being 'worst itch imaginable'. Higher scores indicated worse outcome.
Time frame: Baseline, Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48 and 52
Absolute Change From Baseline in Weekly Average of Average Pruritus NRS Score
Pruritus NRS is a scale that was used by the participants to report the intensity of their pruritus (itch) during the last 24 hours. For maximum itch intensity: the scores were provided on a scale of 0 to 10, with 0 being 'no itch' and 10 being 'worst itch imaginable'. Higher scores indicated worse outcome.
Time frame: Baseline, Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48 and 52
Percent Change From Baseline in Weekly Average of Average Pruritus NRS Score
Pruritus NRS is a scale that was used by the participants to report the intensity of their pruritus (itch) during the last 24 hours. For maximum itch intensity: the scores were provided on a scale of 0 to 10, with 0 being 'no itch' and 10 being 'worst itch imaginable'. Higher scores indicated worse outcome.
Time frame: Baseline, Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48 and 52
Absolute Change From Baseline in Weekly Average of Sleep Disturbance NRS Score
The sleep disturbance NRS is a scale used by the participants to report the degree of their sleep loss related to AD. Participants were asked the following questions in their local language: how would you rate your sleep last night? On a scale of 0 to 10, with 0 being 'no sleep loss related to signs/symptoms of AD' and 10 being 'I cannot sleep at all due to the signs/symptoms of AD'. Higher scores indicated worse outcome.
Time frame: Baseline, Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48 and 52
Percent Change From Baseline in Weekly Average of Sleep Disturbance NRS Score
The sleep disturbance NRS is a scale used by the participants to report the degree of their sleep loss related to AD. Participants were asked the following questions in their local language: how would you rate your sleep last night? On a scale of 0 to 10, with 0 being 'no sleep loss related to signs/symptoms of AD' and 10 being 'I cannot sleep at all due to the signs/symptoms of AD'. Higher scores indicated worse outcome.
Time frame: Baseline, Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48 and 52
Percentage of Participants Receiving Any Rescue Therapy by Rescue Treatment
Percentage of participants receiving any rescue therapy by rescue treatment was reported.
Time frame: From Baseline up to Week 52
Percent Change From Baseline in Scoring Atopic Dermatitis (SCORAD) Score
SCORAD is a clinical tool for assessing the severity and the extent of AD signs and symptoms. Extent and intensity of eczema as well as subjective signs (insomnia, etc.) are assessed and scored. Total score ranged from 0 (absent disease) to 103 (severe disease), a higher score indicated severe disease.
Time frame: Baseline, Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48 and 52
Change From Baseline in Children's Dermatology Life Quality Index (cDLQI) For Participants >=4 Years of Age
The DLQI is a validated 10-item questionnaire covering domains including symptoms/feelings, daily activities, leisure, work/school, personal relationships, and treatment. The participant rated each question ranging from 0 (not at all) to 3 (very much) and score ranged from 0 to 30. A higher total score indicated a poorer quality of life (QoL).
Time frame: Baseline, Week 16 and Week 52
Change From Baseline in Infants' Dermatology Life Quality Index (iDLQI) Score For Participants Less Than (<) 4 Years of Age
The DLQI is a validated 10-item questionnaire covering domains including symptoms/feelings, daily activities, leisure, work/school, personal relationships, and treatment. The participant rated each question ranging from 0 (not at all) to 3 (very much) and score ranged from 0 to 30. A higher total score indicated a poorer QoL.
Time frame: Baseline, Week 16 and Week 52
Change From Baseline in Patient-Oriented Eczema Measure (POEM)
The POEM is a 7-item questionnaire that assessed disease symptoms (dryness, itching, flaking, cracking, sleep loss, bleeding and weeping) with a scoring system of 0 (absent disease) to 28 (severe disease). A high score indicated poor QOL.
Time frame: Baseline, Week 16 and Week 52
Pharmacokinetic (PK)/Pharmacodynamic (PD) Relationship Between Nemolizumab Serum Concentration and Changes in PP NRS
The relationship between nemolizumab serum concentrations and changes in PP-NRS score was established using population point estimate of IC50, where IC50 is the concentration leading to half of the maximum drug-induced reduction (Imax) in PP NRS.
Time frame: Baseline up to Week 52
PK/PD Relationship Between Nemolizumab Serum Concentration and Changes in EASI Score
The relationship between nemolizumab serum concentrations and changes in EASI score was established using population point estimate of IC50. Where, IC50 is the concentration leading to half of the maximum drug-induced reduction (Imax) in EASI score.
Time frame: Baseline up to Week 52
PK/PD Relationship Between Nemolizumab Serum Concentration and Changes in IGA Score
The relationship between nemolizumab serum concentrations and changes in IGA score was established using the population point estimate of the slope parameter.
Time frame: Baseline up to Week 52
Number of Participants With Positive Anti-Drug Antibody (ADA) for Nemolizumab
ADA positive was defined as a sample that was evaluated as positive in both the ADA screening and confirmatory assays. ADA positive participants was defined as participants who had at least 1 positive ADA result.
Time frame: Baseline, Week 16 and Week 52
The study was conducted at 23 sites in the United States, Denmark, Hungary, Poland and Spain from 24 June 2021 to 28 April 2025.
| Milestone | Cohort 1: Participants Aged 7-11 Year | Cohort 1.1: Participants Aged 7-11 Years | Cohort 2: Participants Aged 2-6 Years |
|---|---|---|---|
| Started | 36 | 37 | 36 |
| Completed | 31 | 35 | 32 |
| Not completed | 5 | 2 | 4 |
| Withdrew: Subject/caregiver request | 4 | 0 | 2 |
| Withdrew: Lack of efficacy | 0 | 1 | 1 |
| Withdrew: Adverse event | 1 | 0 | 0 |
| Withdrew: Lost to follow-up | 0 | 0 | 1 |
| Withdrew: Physician/principal investigator decision | 0 | 1 | 0 |
Serum concentrations of Nemolizumab were analyzed using validated enzyme linked immunosorbent assay (ELISA).
| nanograms per milliliters (ng/mL) | Cohort 1: Participants Aged 7-11 Year | Cohort 1.1: Participants Aged 7-11 Years | Cohort 2: Participants Aged 2-6 Years |
|---|---|---|---|
| Week 4 | 5950 ± 2240 | 2900 ± 893 | 3080 ± 1220 |
| Week 8 | 5150 ± 2150 | 2800 ± 986 | 2560 ± 1310 |
| Week 12 | 4730 ± 1670 | 2550 ± 1180 | 2490 ± 1430 |
| Week 16 | 4630 ± 1660 | 2110 ± 1000 | 2430 ± 1510 |
| Week 32 | 4370 ± 2100 | 2760 ± 1150 | 2600 ± 1490 |
| Week 52 | 4410 ± 2490 | 2250 ± 939 | 2680 ± 1490 |
CL/F is apparent clearance of the drug from the serum, calculated as the drug dose divided area under the curve from time 0 extrapolated to infinite time \[AUC (0-inf)\]. Individual nemolizumab.
| liter per day (L/day) | Cohort 1: Participants Aged 7-11 Year | Cohort 1.1: Participants Aged 7-11 Years | Cohort 2: Participants Aged 2-6 Years |
|---|---|---|---|
| Apparent Total Body Clearance (Cl/F) of Nemolizumab | 0.139 ± 0.0824 | 0.134 ± 0.0407 | 0.0761 ± 0.0245 |
Vd/F was calculated as dose divided by lambda\_z \*AUC(0-inf).
| liter | Cohort 1: Participants Aged 7-11 Year | Cohort 1.1: Participants Aged 7-11 Years | Cohort 2: Participants Aged 2-6 Years |
|---|---|---|---|
| Apparent Volume of Distribution (Vd/F) of Nemolizumab | 3.39 ± 1.36 | 3.37 ± 1.02 | 1.75 ± 0.495 |
| per day | Cohort 1: Participants Aged 7-11 Year | Cohort 1.1: Participants Aged 7-11 Years | Cohort 2: Participants Aged 2-6 Years |
|---|---|---|---|
| Absorption Rate Constant (Ka) of Nemolizumab | 0.502 ± 0.0402 | 0.503 ± 0.0280 | 0.494 ± 0.0383 |
| micrograms per milliliter (ug/mL) | Cohort 1: Participants Aged 7-11 Year | Cohort 1.1: Participants Aged 7-11 Years | Cohort 2: Participants Aged 2-6 Years |
|---|---|---|---|
| Week 4 | 6.71 ± 2.76 | 3.25 ± 1.21 | 3.13 ± 1.29 |
| Week 8 | 6.38 ± 3.39 | 3.15 ± 1.51 | 3.20 ± 1.80 |
| Week 12 | 5.35 ± 2.46 | 2.85 ± 1.43 | 2.84 ± 1.38 |
| Week 16 | 5.52 ± 2.54 | 2.69 ± 1.48 | 3.10 ± 1.63 |
| days*nanograms per milliliters | Cohort 1: Participants Aged 7-11 Year | Cohort 1.1: Participants Aged 7-11 Years | Cohort 2: Participants Aged 2-6 Years |
|---|---|---|---|
| Area Under the Serum Concentration-Time Curve From Time Zero to Infinity (AUCinf) of Nemolizumab | 204 ± 61.6 | 101 ± 26.7 | 93.2 ± 38.2 |
| day | Cohort 1: Participants Aged 7-11 Year | Cohort 1.1: Participants Aged 7-11 Years | Cohort 2: Participants Aged 2-6 Years |
|---|---|---|---|
| Apparent Terminal Half-life (t1/2) of Nemolizumab | 17.7 ± 3.89 | 17.8 ± 3.86 | 16.9 ± 5.06 |
AE defined as any untoward medical occurrence in clinical study participant administered a medicinal product which does not necessarily have causal relationship with this treatment. TEAEs defined as AEs occurring after first administration of study drug during the study. SAE was any untoward medical occurrence, in view of either Investigator or Sponsor, that resulted in death, was life-threatening, resulted in inpatient hospitalisation or prolongation of existing hospitalisation, resulted in persistent or significant disability/incapacity, was congenital anomaly/birth defect or was important medical event. AESI was noteworthy TEAE for study drug that was to be monitored closely and reported promptly. Relatedness to study drug was based on Investigator's discretion. AEs Leading to study treatment withdrawal and AEs Leading to study withdrawal will also be reported.
| Participants | Cohort 1: Participants Aged 7-11 Year | Cohort 1.1: Participants Aged 7-11 Years | Cohort 2: Participants Aged 2-6 Years |
|---|---|---|---|
| TEAEs | 30 | 32 | 32 |
| AESIs | 4 | 3 | 1 |
| AE leading to discontinuation | 1 | 0 | 0 |
| SAEs | 0 | 0 | 0 |
EASI assesses severity and extent of AD signs through a composite score of erythema, induration/population, excoriation, and lichenification. The severity was assessed on a scale of 0 (absent) to 3 (severe) for each of the 4 body areas: head/neck, trunk, upper limbs, and lower limbs, with half points allowed. The EASI score ranged from 0 to 72 with higher scores representing greater severity of atopic dermatitis.
| percent change | Cohort 1: Participants Aged 7-11 Year | Cohort 1.1: Participants Aged 7-11 Years | Cohort 2: Participants Aged 2-6 Years |
|---|---|---|---|
| Week 4 | -48.91 ± 32.283 | -66.10 ± 32.089 | -68.88 ± 30.549 |
| Week 8 | -61.40 ± 36.260 | -74.65 ± 28.423 | -75.41 ± 35.869 |
| Week 12 | -66.89 ± 33.873 | -80.49 ± 19.318 | -85.00 ± 19.401 |
| Week 16 | -76.34 ± 25.119 | -85.86 ± 14.305 | -82.17 ± 24.537 |
| Week 20 | -78.31 ± 23.574 | -87.26 ± 15.473 | -88.80 ± 22.292 |
| Week 24 | -78.39 ± 25.594 | -92.62 ± 9.826 | -87.38 ± 21.716 |
| Week 28 | -82.38 ± 19.766 | -88.32 ± 15.212 | -93.28 ± 14.285 |
| Week 32 | -79.09 ± 29.339 | -91.72 ± 9.358 | -88.77 ± 18.080 |
| Week 36 | -84.49 ± 18.584 | -88.90 ± 15.773 | -90.40 ± 15.204 |
| Week 40 | -87.48 ± 13.801 | -88.63 ± 15.316 | -87.16 ± 20.753 |
| Week 44 | -91.51 ± 10.145 | -87.08 ± 21.731 | -89.06 ± 18.792 |
| Week 48 | -91.07 ± 11.622 | -85.49 ± 21.664 | -90.71 ± 16.472 |
| Week 52 | -90.86 ± 10.609 | -85.66 ± 21.397 | -90.53 ± 20.487 |
EASI assesses severity and extent of AD signs through a composite score of erythema, induration/population, excoriation, and lichenification. The severity was assessed on a scale of 0 (absent) to 3 (severe) for each of the 4 body areas: head/neck, trunk, upper limbs, and lower limbs, with half points allowed. The EASI score ranged from 0 to 72 with higher scores representing greater severity of atopic dermatitis.
| score on a scale | Cohort 1: Participants Aged 7-11 Year | Cohort 1.1: Participants Aged 7-11 Years | Cohort 2: Participants Aged 2-6 Years |
|---|---|---|---|
| Week 4 | -12.86 ± 9.154 | -18.90 ± 11.316 | -17.72 ± 8.449 |
| Week 8 | -16.56 ± 12.141 | -20.87 ± 9.960 | -19.51 ± 10.210 |
| Week 12 | -18.00 ± 11.880 | -23.25 ± 9.566 | -21.95 ± 7.247 |
| Week 16 | -20.46 ± 10.189 | -24.27 ± 7.840 | -21.60 ± 8.357 |
| Week 20 | -21.12 ± 10.359 | -24.88 ± 8.290 | -23.34 ± 8.401 |
| Week 24 | -21.19 ± 10.950 | -26.63 ± 8.783 | -22.89 ± 8.483 |
| Week 28 | -22.06 ± 9.332 | -25.10 ± 8.529 | -24.39 ± 7.567 |
| Week 32 | -21.04 ± 10.940 | -25.98 ± 8.246 | -23.48 ± 8.586 |
| Week 36 | -22.67 ± 9.470 | -25.30 ± 9.270 | -23.78 ± 7.532 |
| Week 40 | -23.26 ± 9.041 | -25.44 ± 9.533 | -23.03 ± 8.323 |
| Week 44 | -24.40 ± 9.259 | -25.18 ± 9.720 | -23.44 ± 8.263 |
| Week 48 | -24.45 ± 9.029 | -24.33 ± 9.500 | -23.91 ± 7.981 |
| Week 52 | -24.09 ± 8.791 | -24.24 ± 10.001 | -23.85 ± 8.138 |
EASI assesses severity and extent of AD signs through a composite score of erythema, induration/population, excoriation, and lichenification. The severity was assessed on a scale of 0 (absent) to 3 (severe) for each of the 4 body areas: head/neck, trunk, upper limbs, and lower limbs, with half points allowed. The EASI score ranged from 0 to 72 with higher scores representing greater severity of atopic dermatitis. EASI-50, EASI-75 and EASI-90 responders will be the participants who achieved greater than or equal to (\>=) 50%, \>=75% and \>=90% overall improvement in EASI score respectively from baseline to Week 52.
| Participants | Cohort 1: Participants Aged 7-11 Year | Cohort 1.1: Participants Aged 7-11 Years | Cohort 2: Participants Aged 2-6 Years |
|---|---|---|---|
| Week 4: EASI - 50 | 19 | 25 | 29 |
| Week 4: EASI - 75 | 10 | 18 | 21 |
| Week 4: EASI - 90 | 3 | 13 | 10 |
| Week 8: EASI - 50 | 23 | 31 | 30 |
| Week 8: EASI - 75 | 15 | 24 | 25 |
| Week 8: EASI - 90 | 8 | 16 | 18 |
| Week 12: EASI - 50 | 30 | 31 | 32 |
| Week 12: EASI - 75 | 17 | 25 | 28 |
| Week 12: EASI - 90 | 9 | 15 | 19 |
| Week 16: EASI - 50 | 31 | 34 | 32 |
| Week 16: EASI - 75 | 24 | 27 | 25 |
| Week 16: EASI - 90 | 12 | 19 | 20 |
| Week 20: EASI - 50 | 32 | 34 | 30 |
| Week 20: EASI - 75 | 25 | 30 | 29 |
| Week 20: EASI - 90 | 13 | 18 | 22 |
| Week 24: EASI - 50 | 31 | 34 | 31 |
| Week 24: EASI - 75 | 26 | 31 | 29 |
| Week 24: EASI - 90 | 16 | 25 | 25 |
| Week 28: EASI - 50 | 32 | 33 | 32 |
| Week 28: EASI - 75 | 30 | 31 | 31 |
| Week 28: EASI - 90 | 19 | 21 | 29 |
| Week 32: EASI - 50 | 33 | 35 | 30 |
| Week 32: EASI - 75 | 27 | 33 | 27 |
| Week 32: EASI - 90 | 15 | 25 | 26 |
| Week 36: EASI - 50 | 32 | 34 | 30 |
| Week 36: EASI - 75 | 25 | 31 | 29 |
| Week 36: EASI - 90 | 18 | 24 | 24 |
| Week 40: EASI - 50 | 32 | 34 | 32 |
| Week 40: EASI - 75 | 27 | 29 | 25 |
| Week 40: EASI - 90 | 18 | 23 | 22 |
| Week 44: EASI - 50 | 31 | 32 | 30 |
| Week 44: EASI - 75 | 29 | 29 | 28 |
| Week 44: EASI - 90 | 22 | 24 | 22 |
| Week 48: EASI - 50 | 30 | 32 | 32 |
| Week 48: EASI - 75 | 28 | 28 | 30 |
| Week 48: EASI - 90 | 21 | 22 | 24 |
| Week 52: EASI - 50 | 32 | 33 | 32 |
| Week 52: EASI - 75 | 30 | 29 | 29 |
| Week 52: EASI - 90 | 22 | 20 | 25 |
IGA is a 5-point scale used by the investigator or trained designee to evaluate the global severity of AD. The Investigator reviewed the participant's skin and give a score of 0 (Clear), 1 (Almost clear), 2 (Mild), 3 (Moderate), or 4 (Severe). Here, higher score indicates severe outcome. Success was defined as an IGA of 0 \[Clear\] or 1 \[Almost clear\] and a \>=2-points improvement from baseline. Number of participants with IGA success rate was reported for this outcome measure.
| Participants | Cohort 1: Participants Aged 7-11 Year | Cohort 1.1: Participants Aged 7-11 Years | Cohort 2: Participants Aged 2-6 Years |
|---|---|---|---|
| Week 4 | 5 | 12 | 10 |
| Week 8 | 9 | 17 | 14 |
| Week 12 | 13 | 13 | 18 |
| Week 16 | 17 | 15 | 17 |
| Week 20 | 13 | 19 | 22 |
| Week 24 | 13 | 25 | 22 |
| Week 28 | 14 | 17 | 23 |
| Week 32 | 15 | 23 | 24 |
| Week 36 | 17 | 19 | 20 |
| Week 40 | 14 | 19 | 20 |
| Week 44 | 19 | 19 | 20 |
| Week 48 | 17 | 21 | 24 |
| Week 52 | 15 | 21 | 24 |
BSA affected by AD was assessed for each section of the body (the possible highest score for each region was: head and neck \[9%\], anterior trunk \[18%\], back \[18%\], upper limbs \[18%\], lower limbs \[36%\], and genitals \[1%\]) and reported as a percentage of all major body sections combined. The reported percentage of BSA was combined percentage of all major body sections.
| percentage of BSA involvement | Cohort 1: Participants Aged 7-11 Year | Cohort 1.1: Participants Aged 7-11 Years | Cohort 2: Participants Aged 2-6 Years |
|---|---|---|---|
| Week 4 | -12.76 ± 18.358 | -22.22 ± 19.519 | -17.66 ± 13.779 |
| Week 8 | -17.75 ± 21.082 | -28.34 ± 18.666 | -23.09 ± 17.492 |
| Week 12 | -21.15 ± 20.593 | -32.84 ± 17.714 | -28.15 ± 15.323 |
| Week 16 | -25.50 ± 17.463 | -34.17 ± 15.452 | -25.34 ± 16.319 |
| Week 20 | -26.09 ± 20.817 | -36.46 ± 16.910 | -29.48 ± 14.698 |
| Week 24 | -28.66 ± 18.126 | -37.67 ± 16.934 | -28.74 ± 15.153 |
| Week 28 | -29.99 ± 17.461 | -35.90 ± 16.301 | -31.82 ± 12.338 |
| Week 32 | -28.72 ± 17.295 | -38.15 ± 16.188 | -30.02 ± 14.152 |
| Week 36 | -31.82 ± 15.182 | -37.51 ± 16.869 | -29.18 ± 13.313 |
| Week 40 | -33.15 ± 15.673 | -37.57 ± 17.080 | -28.65 ± 16.538 |
| Week 44 | -34.98 ± 17.161 | -35.42 ± 19.669 | -28.96 ± 17.460 |
| Week 48 | -35.49 ± 16.827 | -36.10 ± 18.255 | -31.70 ± 14.324 |
| Week 52 | -34.71 ± 16.319 | -35.27 ± 17.668 | -31.15 ± 15.041 |
Pruritus NRS is a scale that will be used by the participants to report the intensity of their pruritus (itch) during the last 24 hours. For maximum itch intensity: the scores were provided on a scale of 0 to 10, with 0 being 'no itch' and 10 being 'worst itch imaginable'. Higher scores indicated worse outcome.
| score on a scale | Cohort 1: Participants Aged 7-11 Year | Cohort 1.1: Participants Aged 7-11 Years | Cohort 2: Participants Aged 2-6 Years |
|---|---|---|---|
| Week 4 | -2.78 ± 2.066 | -3.03 ± 2.470 | -4.36 ± 2.902 |
| Week 8 | -3.91 ± 2.266 | -4.29 ± 2.292 | -4.84 ± 2.516 |
| Week 12 | -4.13 ± 2.167 | -4.47 ± 2.487 | -5.03 ± 2.573 |
| Week 16 | -4.60 ± 2.055 | -4.90 ± 2.491 | -5.48 ± 2.454 |
| Week 20 | -4.22 ± 2.221 | -4.87 ± 2.259 | -5.54 ± 2.534 |
| Week 24 | -4.46 ± 2.264 | -5.16 ± 2.257 | -5.85 ± 2.424 |
| Week 28 | -4.58 ± 2.089 | -5.40 ± 1.984 | -5.78 ± 2.439 |
| Week 32 | -4.71 ± 2.187 | -5.39 ± 2.069 | -5.72 ± 2.363 |
| Week 36 | -4.88 ± 1.995 | -5.50 ± 2.125 | -5.94 ± 2.348 |
| Week 40 | -4.88 ± 1.957 | -5.41 ± 2.087 | -6.16 ± 2.256 |
| Week 44 | -4.65 ± 2.008 | -5.56 ± 2.186 | -6.26 ± 1.991 |
| Week 48 | -4.56 ± 2.120 | -5.81 ± 2.156 | -6.46 ± 1.978 |
| Week 52 | -4.66 ± 2.090 | -5.62 ± 1.944 | -6.32 ± 2.129 |
Pruritus NRS is a scale that was used by the participants to report the intensity of their pruritus (itch) during the last 24 hours. For maximum itch intensity: the scores were provided on a scale of 0 to 10, with 0 being 'no itch' and 10 being 'worst itch imaginable'. Higher scores indicated worse outcome.
| percent change | Cohort 1: Participants Aged 7-11 Year | Cohort 1.1: Participants Aged 7-11 Years | Cohort 2: Participants Aged 2-6 Years |
|---|---|---|---|
| Week 4 | -38.15 ± 27.090 | -41.48 ± 32.040 | -57.89 ± 39.240 |
| Week 8 | -53.41 ± 29.280 | -58.95 ± 29.795 | -65.90 ± 33.824 |
| Week 12 | -57.56 ± 29.073 | -60.29 ± 30.314 | -68.08 ± 33.578 |
| Week 16 | -63.84 ± 27.986 | -66.58 ± 29.990 | -74.15 ± 31.042 |
| Week 20 | -59.75 ± 30.193 | -67.09 ± 28.155 | -75.40 ± 32.320 |
| Week 24 | -62.19 ± 31.021 | -70.43 ± 26.843 | -79.15 ± 28.563 |
| Week 28 | -64.67 ± 28.794 | -73.91 ± 24.040 | -78.51 ± 29.041 |
| Week 32 | -64.67 ± 27.737 | -73.55 ± 26.034 | -77.65 ± 28.477 |
| Week 36 | -68.77 ± 27.082 | -75.57 ± 26.533 | -80.28 ± 27.557 |
| Week 40 | -68.79 ± 26.011 | -73.64 ± 25.659 | -82.39 ± 26.173 |
| Week 44 | -65.80 ± 26.928 | -75.99 ± 26.893 | -84.51 ± 22.644 |
| Week 48 | -64.86 ± 28.322 | -78.89 ± 25.842 | -86.72 ± 20.254 |
| Week 52 | -65.73 ± 27.817 | -75.85 ± 23.800 | -84.82 ± 24.430 |
Pruritus NRS is a scale that was used by the participants to report the intensity of their pruritus (itch) during the last 24 hours. For maximum itch intensity: the scores were provided on a scale of 0 to 10, with 0 being 'no itch' and 10 being 'worst itch imaginable'. Higher scores indicated worse outcome.
| percentage of participants | Cohort 1: Participants Aged 7-11 Year | Cohort 1.1: Participants Aged 7-11 Years | Cohort 2: Participants Aged 2-6 Years |
|---|---|---|---|
| Week 4 | 23.5 | 31.4 | 69.4 |
| Week 8 | 44.4 | 64.7 | 66.7 |
| Week 12 | 50.0 | 64.7 | 69.4 |
| Week 16 | 58.8 | 66.7 | 76.5 |
| Week 20 | 54.5 | 75.0 | 78.1 |
| Week 24 | 59.4 | 67.7 | 80.6 |
| Week 28 | 60.6 | 77.4 | 81.8 |
| Week 32 | 58.6 | 81.3 | 78.8 |
| Week 36 | 66.7 | 80.6 | 84.4 |
| Week 40 | 69.0 | 82.4 | 86.2 |
| Week 44 | 61.3 | 78.8 | 90.0 |
| Week 48 | 65.5 | 81.3 | 92.0 |
| Week 52 | 65.4 | 80.0 | 88.5 |
Pruritus NRS is a scale that was used by the participants to report the intensity of their pruritus (itch) during the last 24 hours. For maximum itch intensity: the scores were provided on a scale of 0 to 10, with 0 being 'no itch' and 10 being 'worst itch imaginable'. Higher scores indicated worse outcome.
| score on a scale | Cohort 1: Participants Aged 7-11 Year | Cohort 1.1: Participants Aged 7-11 Years | Cohort 2: Participants Aged 2-6 Years |
|---|---|---|---|
| Week 4 | -2.46 ± 1.878 | -2.84 ± 2.286 | -4.26 ± 2.884 |
| Week 8 | -3.61 ± 2.030 | -4.14 ± 2.111 | -4.64 ± 2.477 |
| Week 12 | -3.83 ± 1.889 | -4.28 ± 2.303 | -4.89 ± 2.569 |
| Week 16 | -4.27 ± 1.884 | -4.61 ± 2.363 | -5.29 ± 2.512 |
| Week 20 | -4.04 ± 1.831 | -4.61 ± 2.260 | -5.29 ± 2.539 |
| Week 24 | -4.38 ± 1.939 | -5.01 ± 2.145 | -5.60 ± 2.411 |
| Week 28 | -4.32 ± 1.818 | -5.04 ± 1.977 | -5.55 ± 2.403 |
| Week 32 | -4.40 ± 1.909 | -5.00 ± 2.049 | -5.48 ± 2.309 |
| Week 36 | -4.65 ± 1.733 | -4.96 ± 2.204 | -5.68 ± 2.301 |
| Week 40 | -4.59 ± 1.757 | -5.03 ± 2.108 | -5.89 ± 2.214 |
| Week 44 | -4.55 ± 1.738 | -5.08 ± 2.318 | -5.96 ± 1.942 |
| Week 48 | -4.42 ± 1.843 | -5.30 ± 2.261 | -6.06 ± 1.992 |
| Week 52 | -4.53 ± 1.729 | -5.19 ± 2.054 | -5.89 ± 2.050 |
Pruritus NRS is a scale that was used by the participants to report the intensity of their pruritus (itch) during the last 24 hours. For maximum itch intensity: the scores were provided on a scale of 0 to 10, with 0 being 'no itch' and 10 being 'worst itch imaginable'. Higher scores indicated worse outcome.
| percent change | Cohort 1: Participants Aged 7-11 Year | Cohort 1.1: Participants Aged 7-11 Years | Cohort 2: Participants Aged 2-6 Years |
|---|---|---|---|
| Week 4 | -38.07 ± 28.816 | -42.77 ± 32.130 | -60.43 ± 40.923 |
| Week 8 | -55.69 ± 30.791 | -62.42 ± 29.260 | -66.94 ± 34.327 |
| Week 12 | -59.59 ± 29.263 | -63.40 ± 29.376 | -69.71 ± 34.020 |
| Week 16 | -65.85 ± 28.875 | -68.84 ± 29.502 | -75.35 ± 31.973 |
| Week 20 | -63.23 ± 28.263 | -69.59 ± 29.258 | -76.24 ± 32.756 |
| Week 24 | -66.58 ± 29.303 | -75.37 ± 25.933 | -79.72 ± 28.575 |
| Week 28 | -67.41 ± 27.925 | -76.56 ± 25.092 | -80.01 ± 28.807 |
| Week 32 | -67.17 ± 27.445 | -76.66 ± 27.287 | -78.86 ± 27.818 |
| Week 36 | -72.15 ± 26.282 | -76.63 ± 28.952 | -81.52 ± 26.943 |
| Week 40 | -71.45 ± 25.950 | -76.29 ± 26.727 | -83.27 ± 25.987 |
| Week 44 | -71.06 ± 26.279 | -77.24 ± 30.172 | -85.78 ± 21.530 |
| Week 48 | -69.56 ± 28.108 | -80.56 ± 28.317 | -87.22 ± 20.586 |
| Week 52 | -71.11 ± 26.493 | -78.63 ± 27.303 | -85.40 ± 24.213 |
The sleep disturbance NRS is a scale used by the participants to report the degree of their sleep loss related to AD. Participants were asked the following questions in their local language: how would you rate your sleep last night? On a scale of 0 to 10, with 0 being 'no sleep loss related to signs/symptoms of AD' and 10 being 'I cannot sleep at all due to the signs/symptoms of AD'. Higher scores indicated worse outcome.
| score on a scale | Cohort 1: Participants Aged 7-11 Year | Cohort 1.1: Participants Aged 7-11 Years | Cohort 2: Participants Aged 2-6 Years |
|---|---|---|---|
| Week 4 | -2.22 ± 1.731 | -2.87 ± 2.348 | -4.49 ± 3.038 |
| Week 8 | -3.22 ± 1.957 | -4.04 ± 2.022 | -4.91 ± 2.637 |
| Week 12 | -3.58 ± 1.875 | -4.09 ± 2.439 | -5.26 ± 2.758 |
| Week 16 | -4.02 ± 1.770 | -4.43 ± 2.608 | -5.50 ± 2.590 |
| Week 20 | -3.90 ± 1.968 | -4.40 ± 2.459 | -5.43 ± 2.646 |
| Week 24 | -4.05 ± 1.947 | -4.76 ± 2.452 | -5.79 ± 2.358 |
| Week 28 | -4.10 ± 1.903 | -4.87 ± 2.436 | -5.70 ± 2.382 |
| Week 32 | -4.24 ± 2.014 | -4.93 ± 2.435 | -5.69 ± 2.449 |
| Week 36 | -4.27 ± 1.948 | -4.92 ± 2.448 | -5.75 ± 2.408 |
| Week 40 | -4.29 ± 1.977 | -4.97 ± 2.332 | -5.99 ± 2.338 |
| Week 44 | -4.22 ± 2.032 | -5.06 ± 2.454 | -5.93 ± 2.218 |
| Week 48 | -4.28 ± 2.013 | -5.19 ± 2.486 | -5.98 ± 2.235 |
| Week 52 | -4.25 ± 1.830 | -5.02 ± 2.235 | -5.87 ± 2.262 |
The sleep disturbance NRS is a scale used by the participants to report the degree of their sleep loss related to AD. Participants were asked the following questions in their local language: how would you rate your sleep last night? On a scale of 0 to 10, with 0 being 'no sleep loss related to signs/symptoms of AD' and 10 being 'I cannot sleep at all due to the signs/symptoms of AD'. Higher scores indicated worse outcome.
| percent change | Cohort 1: Participants Aged 7-11 Year | Cohort 1.1: Participants Aged 7-11 Years | Cohort 2: Participants Aged 2-6 Years |
|---|---|---|---|
| Week 4 | -39.21 ± 29.647 | -42.47 ± 38.448 | -62.43 ± 39.978 |
| Week 8 | -56.84 ± 31.138 | -62.31 ± 29.147 | -70.03 ± 34.843 |
| Week 12 | -61.78 ± 28.132 | -61.71 ± 34.954 | -73.73 ± 34.420 |
| Week 16 | -69.67 ± 23.842 | -66.11 ± 36.736 | -77.79 ± 31.422 |
| Week 20 | -68.61 ± 27.927 | -67.56 ± 35.387 | -77.67 ± 32.456 |
| Week 24 | -68.90 ± 28.233 | -72.08 ± 34.295 | -82.82 ± 27.889 |
| Week 28 | -71.86 ± 26.979 | -73.97 ± 34.922 | -81.60 ± 28.432 |
| Week 32 | -71.80 ± 27.867 | -74.49 ± 34.085 | -81.22 ± 28.812 |
| Week 36 | -73.75 ± 26.730 | -75.55 ± 34.652 | -81.62 ± 27.706 |
| Week 40 | -72.04 ± 27.324 | -76.49 ± 32.641 | -84.88 ± 27.123 |
| Week 44 | -73.08 ± 28.123 | -77.93 ± 34.758 | -84.54 ± 24.702 |
| Week 48 | -72.93 ± 28.940 | -79.38 ± 34.445 | -86.16 ± 24.318 |
| Week 52 | -75.37 ± 25.904 | -77.67 ± 33.804 | -84.52 ± 25.893 |
Percentage of participants receiving any rescue therapy by rescue treatment was reported.
| percentage of participants | Cohort 1: Participants Aged 7-11 Year | Cohort 1.1: Participants Aged 7-11 Years | Cohort 2: Participants Aged 2-6 Years |
|---|---|---|---|
| Percentage of Participants Receiving Any Rescue Therapy by Rescue Treatment | 13.9 | 2.7 | 5.6 |
SCORAD is a clinical tool for assessing the severity and the extent of AD signs and symptoms. Extent and intensity of eczema as well as subjective signs (insomnia, etc.) are assessed and scored. Total score ranged from 0 (absent disease) to 103 (severe disease), a higher score indicated severe disease.
| percent change | Cohort 1: Participants Aged 7-11 Year | Cohort 1.1: Participants Aged 7-11 Years | Cohort 2: Participants Aged 2-6 Years |
|---|---|---|---|
| Week 4 | -35.91 ± 21.912 | -49.08 ± 24.712 | -55.04 ± 21.867 |
| Week 8 | -50.33 ± 20.729 | -59.01 ± 20.163 | -61.09 ± 26.870 |
| Week 12 | -58.29 ± 22.692 | -63.16 ± 20.228 | -70.53 ± 20.369 |
| Week 16 | -58.98 ± 22.159 | -67.97 ± 18.005 | -68.07 ± 24.199 |
| Week 20 | -58.82 ± 22.867 | -72.33 ± 17.542 | -75.46 ± 22.982 |
| Week 24 | -58.83 ± 24.493 | -76.31 ± 13.598 | -76.18 ± 21.189 |
| Week 28 | -65.51 ± 20.193 | -73.53 ± 15.894 | -80.23 ± 21.501 |
| Week 32 | -59.52 ± 27.109 | -76.59 ± 15.176 | -75.58 ± 18.677 |
| Week 36 | -66.96 ± 22.759 | -72.88 ± 15.971 | -75.29 ± 19.712 |
| Week 40 | -68.57 ± 20.930 | -71.55 ± 17.978 | -74.90 ± 22.125 |
| Week 44 | -73.70 ± 17.943 | -71.51 ± 18.440 | -77.16 ± 19.573 |
| Week 48 | -73.29 ± 19.494 | -72.97 ± 24.220 | -76.82 ± 18.174 |
| Week 52 | -72.03 ± 17.223 | -74.60 ± 20.382 | -79.09 ± 19.268 |
The DLQI is a validated 10-item questionnaire covering domains including symptoms/feelings, daily activities, leisure, work/school, personal relationships, and treatment. The participant rated each question ranging from 0 (not at all) to 3 (very much) and score ranged from 0 to 30. A higher total score indicated a poorer quality of life (QoL).
| score on a scale | Cohort 1: Participants Aged 7-11 Year | Cohort 1.1: Participants Aged 7-11 Years | Cohort 2: Participants Aged 2-6 Years |
|---|---|---|---|
| Week 16 | -9.78 ± 5.966 | -10.80 ± 6.411 | -10.52 ± 5.662 |
| Week 52 | -10.72 ± 6.519 | -11.97 ± 6.037 | -12.00 ± 4.231 |
The DLQI is a validated 10-item questionnaire covering domains including symptoms/feelings, daily activities, leisure, work/school, personal relationships, and treatment. The participant rated each question ranging from 0 (not at all) to 3 (very much) and score ranged from 0 to 30. A higher total score indicated a poorer QoL.
| score on a scale | Cohort 2: Participants Aged 2-6 Years |
|---|---|
| Week 16 | -13.00 ± 4.492 |
| Week 52 | -13.27 ± 6.915 |
The POEM is a 7-item questionnaire that assessed disease symptoms (dryness, itching, flaking, cracking, sleep loss, bleeding and weeping) with a scoring system of 0 (absent disease) to 28 (severe disease). A high score indicated poor QOL.
| score on a scale | Cohort 1: Participants Aged 7-11 Year | Cohort 1.1: Participants Aged 7-11 Years | Cohort 2: Participants Aged 2-6 Years |
|---|---|---|---|
| Week 16 | -12.31 ± 6.851 | -13.71 ± 6.939 | -12.09 ± 8.013 |
| Week 52 | -13.31 ± 6.398 | -14.77 ± 7.026 | -15.53 ± 7.375 |
The relationship between nemolizumab serum concentrations and changes in PP-NRS score was established using population point estimate of IC50, where IC50 is the concentration leading to half of the maximum drug-induced reduction (Imax) in PP NRS.
| ug/mL | Nemolizumab: All Participants |
|---|---|
| Pharmacokinetic (PK)/Pharmacodynamic (PD) Relationship Between Nemolizumab Serum Concentration and Changes in PP NRS | 0.719 |
The relationship between nemolizumab serum concentrations and changes in EASI score was established using population point estimate of IC50. Where, IC50 is the concentration leading to half of the maximum drug-induced reduction (Imax) in EASI score.
| ug/mL | Nemolizumab: All Participants |
|---|---|
| PK/PD Relationship Between Nemolizumab Serum Concentration and Changes in EASI Score | 4.58 |
The relationship between nemolizumab serum concentrations and changes in IGA score was established using the population point estimate of the slope parameter.
| liter per micrograms (L/ug) | Nemolizumab: All Participants |
|---|---|
| PK/PD Relationship Between Nemolizumab Serum Concentration and Changes in IGA Score | 0.09160 |
ADA positive was defined as a sample that was evaluated as positive in both the ADA screening and confirmatory assays. ADA positive participants was defined as participants who had at least 1 positive ADA result.
| Participants | Cohort 1: Participants Aged 7-11 Year | Cohort 1.1: Participants Aged 7-11 Years | Cohort 2: Participants Aged 2-6 Years |
|---|---|---|---|
| Week 16 | 2 | 0 | 0 |
| Week 52 | 3 | 0 | 0 |
Collected over From Baseline up to Week 60. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Cohort 1: Participants Aged 7-11 Year | 0/36 (0%) | 0/36 (0%) | 30/36 (83.3%) |
| Cohort 1.1: Participants Aged 7-11 Years | 0/37 (0%) | 0/37 (0%) | 32/37 (86.5%) |
| Cohort 2: Participants Aged 2-6 Years | 0/36 (0%) | 0/36 (0%) | 32/36 (88.9%) |
| Event | Cohort 1: Participants Aged 7-11 Year | Cohort 1.1: Participants Aged 7-11 Years | Cohort 2: Participants Aged 2-6 Years |
|---|---|---|---|
| Upper respiratory tract infectionInfections and infestations | 11/36 | 11/37 | 16/36 |
| NasopharyngitisInfections and infestations | 1/36 | 7/37 | 6/36 |
| BronchitisInfections and infestations | 2/36 | 3/37 | 6/36 |
| InfluenzaInfections and infestations | 0/36 | 1/37 | 6/36 |
| VaricellaInfections and infestations | 1/36 | 1/37 | 5/36 |
| ImpetigoInfections and infestations | 4/36 | 2/37 | 3/36 |
| ConjunctivitisInfections and infestations | 0/36 | 1/37 | 3/36 |
| GastroenteritisInfections and infestations | 2/36 | 2/37 | 3/36 |
| Otitis mediaInfections and infestations | 1/36 | 0/37 | 3/36 |
| PharyngitisInfections and infestations | 3/36 | 0/37 | 1/36 |
Analysis was performed on all enrolled participants. The Enrolled Set included all participants who met the inclusion/exclusion criteria and signed the informed consent form (ICF) and all individuals who did not met the inclusion/exclusion criteria but received at least 1 dose of study drug.
| Age, Continuous(years) | Cohort 1: Participants Aged 7-11 Year | Cohort 1.1: Participants Aged 7-11 Years | Cohort 2: Participants Aged 2-6 Years | Total |
|---|---|---|---|---|
| Mean | 8.9 ± 1.51 | 8.6 ± 1.40 | 3.8 ± 1.19 | 7.1 ± 2.70 |
| Sex: Female, Male(Participants) | Cohort 1: Participants Aged 7-11 Year | Cohort 1.1: Participants Aged 7-11 Years | Cohort 2: Participants Aged 2-6 Years | Total |
|---|---|---|---|---|
| Female | 17 | 18 | 17 | 52 |
| Male | 19 | 19 | 19 | 57 |
| Ethnicity (NIH/OMB)(Participants) | Cohort 1: Participants Aged 7-11 Year | Cohort 1.1: Participants Aged 7-11 Years | Cohort 2: Participants Aged 2-6 Years | Total |
|---|---|---|---|---|
| Hispanic or Latino | 3 | 0 | 1 | 4 |
| Not Hispanic or Latino | 33 | 37 | 35 | 105 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Cohort 1: Participants Aged 7-11 Year | Cohort 1.1: Participants Aged 7-11 Years | Cohort 2: Participants Aged 2-6 Years | Total |
|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 |
| Asian | 0 | 0 | 0 | 0 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 1 | 1 |
| White | 36 | 37 | 35 | 108 |
| More than one race | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Jun 2021 to primary completion in Apr 2025, 46 months.
Results were first posted in May 2026, 1 year after primary completion.
Of 196 industry-sponsored phase 2 interventional studies under Dermatitis, Atopic, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 17. This study's 46 months is above that.
Counting every sponsor, half of 224 studies reached it within 14 months; a quarter within 10 and three quarters within 19.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Nemolizumab